Избыточное рубцевание в хирургии глаукомы. Часть 3. Методы предоперационной профилактики
https://doi.org/10.21516/2072-0076-2025-18-2-153-159
Аннотация
Изучение факторов профилактики избыточного рубцевания при антиглаукомной хирургии создает фундамент для разработки методов воздействия на эти процессы в послеоперационном периоде с целью повышения эффективности вмешательства. Анализ литературы показал, что систематизированный подход к подготовке успешного оперативного лечения глаукомы должен включать рациональный выбор предшествующей гипотензивной терапии с бесконсервантными препаратами, профилактику повреждений глазной поверхности с применением слезозаместительной и иммуносупрессивной терапии, а также предоперационную противовоспалительную профилактику стероидными и нестероидными средствами с доказанной офтальмогипертензионной безопасностью.
Об авторах
С. Ю. Петров
ФГБУ «НМИЦ глазных болезней им. Гельмгольца» Минздрава России
Россия
Россия
Петров Сергей Юрьевич — д-р мед. наук, начальник отдела глаукомы.
ул. Садовая-Черногрязская, д. 14/19, Москва, 105062
Е. В. Яни
ФГБУ «НМИЦ глазных болезней им. Гельмгольца» Минздрава России
Россия
Россия
Яни Елена Владимировна — канд. мед. наук, руководитель отдела инфекционных и аллергических заболеваний глаз.
ул. Садовая-Черногрязская, д. 14/19, Москва, 105062
О. М. Филиппова
ФГБУ «НМИЦ глазных болезней им. Гельмгольца» Минздрава России
Россия
Россия
Филиппова Ольга Маратовна — канд. мед. наук, научный сотрудник отдела глаукомы.
ул. Садовая-Черногрязская, д. 14/19, Москва, 105062
А. Д. Епхиева
ФГБУ «НМИЦ глазных болезней им. Гельмгольца» Минздрава России
Россия
Россия
Епхиева Анжела Давидовна — аспирант.
ул. Садовая-Черногрязская, д. 14/19, Москва, 105062
Список литературы
1. Mai DD, Ingram Z, Oberfeld B, Sola-Del Valle D. Combined microinvasive glaucoma surgery - A review of the literature and future directions. Semin Ophthalmol. 2023; 38 (6): 529–36. doi:10.1080/08820538.2023.2181665
2. Meshksar A, Razeghinejhad MR, Azimi A. Ab-interno trabeculotomy procedures: A review. J Curr Ophthalmol. 2023; 35 (2): 110–24. doi:10.4103/joco.joco_45_23
3. Traverso CE, Carassa RG, Fea AM, et al. Effectiveness and safety of xen gel stent in glaucoma surgery: A systematic review of the literature. J Clin Med. 2023; 12 (16). doi:10.3390/jcm12165339
4. Измайлова Н.С., Петров С.Ю., Дзебисова А.Д. Избыточное рубцевание в хирургии глаукомы. Часть 1. Морфология рубцового процесса. Российский офтальмологический журнал. 2024; 17 (4): 116–20. https://doi.org/10.21516/2072-0076-2024-17-4-116-120
5. Измайлова Н.С., Петров С.Ю., Епхиева А.Д. Избыточное рубцевание в хирургии глаукомы. Часть 2. Факторы риска. Российский офтальмологический журнал. 2025; 18 (1): 145–9. https://doi.org/10.21516/2072-0076-2025-18-1-145-149
6. Yu DY, Morgan WH, Sun X, et al. The critical role of the conjunctiva in glaucoma filtration surgery. Prog Retin Eye Res. 2009; 28 (5): 303–28. doi:10.1016/j.preteyeres.2009.06.004
7. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007; 5 (2): 75–92. doi:10.1016/s1542-0124(12)70081-2
8. Barabino S, Aragona P, di Zazzo A, Rolando M, with the contribution of selected ocular surface experts from the Societa Italiana di Dacriologia e Superficie O. Updated definition and classification of dry eye disease: Renewed proposals using the nominal group and Delphi techniques. Eur J Ophthalmol. 2021; 31 (1): 42–8. doi:10.1177/1120672120960586
9. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002; 86 (4): 418–23. doi:10.1136/bjo.86.4.418
10. Fechtner RD, Godfrey DG, Budenz D, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010; 29 (6): 618–21. doi:10.1097/ICO.0b013e3181c325b2
11. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008; 17 (5): 350–35. doi:10.1097/IJG.0b013e31815c5f4f
12. Rossi GC, Tinelli C, Pasinetti GM, Milano G, Bianchi PE. Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol. 2009; 19 (4): 572–9. doi:10.1177/112067210901900409
13. Thorne JE, Anhalt GJ, Jabs DA. Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology. 2004; 111 (1): 45–52. doi:10.1016/j.ophtha.2003.03.001
14. Arita R, Itoh K, Maeda S, et al. Comparison of the long-term effects of various topical antiglaucoma medications on meibomian glands. Cornea. 2012; 31 (11): 1229–34. doi:10.1097/ICO.0b013e31823f8e7d
15. Petounis AD, Akritopoulos P. Influence of topical and systemic beta-blockers on tear production. Int Ophthalmol. 1989; 13 (1–2): 75–80. doi:10.1007/BF02028642
16. Aydin Kurna S, Acikgoz S, Altun A, et al. The effects of topical antiglaucoma drugs as monotherapy on the ocular surface: a prospective study. J Ophthalmol. 2014; 2014: 460483. doi:10.1155/2014/460483
17. Rabinowitz MP, Katz LJ, Moster M.R, et al. Unilateral prostaglandin-associated periorbitopathy: a syndrome involving upper eyelid retraction distinguishable from the aging sunken eyelid. Ophthalmic Plast Reconstr Surg. 2015; 31 (5): 373–8. doi:10.1097/IOP.0000000000000351
18. Figus M, Nardi M, Piaggi P, et al. Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients. Eye (Lond). 2014; 28 (4): 422–9. doi:10.1038/eye.2013.304
19. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004; 23 (5): 490–6. doi:10.1097/01.ico.0000116526.57227.82
20. Schuman JS, Horwitz B, Choplin NT, et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol. 1997; 115 (7): 847–52. doi:10.1001/archopht.1997.01100160017002
21. Kamath AP, Satyanarayana S, Rodrigues F. Ocular surface changes in primary open angle glaucoma with long term topical anti glaucoma medication. Med J Armed Forces India. 2007; 63 (4): 341–5. doi:10.1016/S0377-1237(07)80011-6
22. Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002; 11 (2): 119–26. doi:10.1097/00061198-200204000-00007
23. Corrales RM, Stern ME, De Paiva CS, et al. Desiccating stress stimulates expression of matrix metalloproteinases by the corneal epithelium. Invest Ophthalmol Vis Sci. 2006; 47 (8): 3293–302. doi:10.1167/iovs.05-1382
24. Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol. 1994; 112 (11): 1437–45. doi:10.1001/archopht.1994.01090230051020
25. Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology. 1999; 106 (3): 556–63. doi:10.1016/S0161-6420(99)90116-1
26. Serle JB, Katz LJ, McLaurin E, et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho Kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2). Am J Ophthalmol. 2018; 186: 116–27. doi:10.1016/j.ajo.2017.11.019
27. Zaman F, Gieser SC, Schwartz GF, Swan C, Williams JM. A multicenter, open-label study of netarsudil for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension in a real-world setting. Curr Med Res Opin. 2021; 37 (6): 1011–20. doi:10.1080/03007995.2021.1901222
28. Weinreb RN, Liebmann JM, Martin KR, Kaufman PL, Vittitow JL. Latanoprostene Bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: Pooled phase 3 study findings. J Glaucoma. 2018; 27 (1): 7–15. doi:10.1097/IJG.0000000000000831
29. Chen W, Zhang Z, Hu J, et al. Changes in rabbit corneal innervation induced by the topical application of benzalkonium chloride. Cornea. 2013; 32 (12): 1599–606. doi:10.1097/ICO.0b013e3182a8196f
30. Baratz KH, Nau CB, Winter EJ, et al. Effects of glaucoma medications on corneal endothelium, keratocytes, and subbasal nerves among participants in the ocular hypertension treatment study. Cornea. 2006; 25 (9): 1046–52. doi:10.1097/01.ico.0000230499.07273.c5
31. Lee SE, Lim HB, Oh S, Lee K, Lee SB. Effects of topical anti-glaucoma medications on outcomes of endoscopic dacryocystorhinostomy: Comparison with age- and sex-matched controls. J Clin Med. 2024; 13 (2). doi:10.3390/jcm13020634
32. Stevens AM, Kestelyn PA, De Bacquer D, Kestelyn PG. Benzalkonium chloride induces anterior chamber inflammation in previously untreated patients with ocular hypertension as measured by flare meter: a randomized clinical trial. Acta Ophthalmol. 2012; 90 (3): e221-224. doi:10.1111/j.1755-3768.2011.02338.x
33. Sherwood MB, Grierson I, Millar L, Hitchings RA. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. Ophthalmology. 1989; 96 (3): 327–35. doi:10.1016/s0161-6420(89)32888-0
34. Baudouin C, Garcher C, Haouat N, Bron A, Gastaud P. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology. 1994; 101 (3): 454–60. doi:10.1016/s0161-6420(94)31322-4
35. Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci. 2004; 45 (5): 1360–8. doi:10.1167/iovs.03-1067
36. Pauly A, Meloni M, Brignole-Baudouin F, Warnet JM, Baudouin C. Multiple endpoint analysis of the 3D-reconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damage. Invest Ophthalmol Vis Sci. 2009; 50 (4): 1644–52. doi:10.1167/iovs.08-2992
37. Lavin MJ, Wormald RP, Migdal CS, Hitchings R.A. The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol. 1990; 108 (11): 1543–8. doi:10.1001/archopht.1990.01070130045027
38. Tailor R, Batra R, Mohamed S. A National survey of glaucoma specialists on the preoperative (Trabeculectomy) management of the ocular surface. Semin Ophthalmol. 2016; 31 (6): 519–25. doi:10.3109/08820538.2014.986585
39. Lorenz K, Wasielica-Poslednik J, Bell K, et al. Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma. PLoS One. 2017; 12 (2): e0171636. doi:10.1371/journal.pone.0171636
40. Bron A, Chiambaretta F, Pouliquen P, Rigal D, Rouland JF. [Efficacy and safety of substituting a twice-daily regimen of timolol with a single daily instillation of nonpreserved beta-blocker in patients with chronic glaucoma or ocular hypertension]. J Fr Ophtalmol. 2003; 26 (7): 668–74. 2003 Sep; 26 (7): 668–74. French. PMID: 13130253.
41. Campagna P, Macri A, Rolando M, Calabria G. Chronic topical eye preservativefree beta-blocker therapy effect on the ocular surface in glaucomatous patients. Acta Ophthalmol Scand Suppl. 1997; 224: 53. doi:10.1111/j.1600-0420.1997.tb00480.x
42. Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010; 88 (3): 329–36. doi:10.1111/j.1755-3768.2010.01907.x
43. Каменских Т.Г., Веселова Е.В., Колбенев И.О., Петрова Ю.В. Влияние различных консервантов на состояние роговицы при инстилляции аналогов простагландинов. Национальный журнал Глаукома. 2015; 14 (3): 49–57.
44. Gandolfi S, Paredes T, Goldberg I, et al. Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma. Eur J Ophthalmol. 2012; 22 (1): 34–44. doi:10.5301/ejo.5000001
45. Gimenez-Gomez R, Garcia-Catalan MR, Gallardo-Galera JM. Tear clearance and ocular symptoms in patients treated with preservative-free prostaglandins. Arch Soc Esp Oftalmol. 2013; 88 (3): 88–91. doi:10.1016/j.oftal.2012.06.003
46. Armaly M.F. Effect of corticosteroids on intraocular pressure and fluid dynamics. Ii. The effect of dexamethasone in the glaucomatous eye. Arch Ophthalmol. 1963; 70: 492–9. doi:10.1001/archopht.1963.00960050494011
47. Roberti G, Oddone F, Agnifili L, et al. Steroid-induced glaucoma: Epidemiology, pathophysiology, and clinical management. Surv Ophthalmol. 2020; 65 (4): 458–72. doi:10.1016/j.survophthal.2020.01.002
48. Lewis JM, Priddy T, Judd J, et al. Intraocular pressure response to topical dexamethasone as a predictor for the development of primary open-angle glaucoma. Am J Ophthalmol. 1988; 106 (5): 607–12. doi:10.1016/0002-9394(88)90595-8
49. Cantrill HL, Palmberg PF, Zink HA, et al. Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am J Ophthalmol. 1975; 79 (6): 1012–7. doi:10.1016/0002-9394(75)90687-x
50. Mindel JS, Tavitian HO, Smith H, Jr, Walker EC. Comparative ocular pressure elevation by medrysone, fluorometholone, and dexamethasone phosphate. Arch Ophthalmol. 1980; 98 (9): 1577–8. doi:10.1001/archopht.1980.01020040429006
51. Broadway DC, Grierson I, Sturmer J, Hitchings RA. Reversal of topical antiglaucoma medication effects on the conjunctiva. Arch Ophthalmol. 1996; 114 (3): 262–7. doi:10.1001/archopht.1996.01100130258004
52. Baudouin C, Nordmann JP, Denis P, et al. Efficacy of indomethacin 0.1% and fluorometholone 0.1% on conjunctival inflammation following chronic application of antiglaucomatous drugs. Graefes Arch Clin Exp Ophthalmol. 2002; 240 (11): 929–35. doi:10.1007/s00417-002-0581-9
53. Nguyen KD, Lee DA. Effect of steroids and nonsteroidal anti-inflammatory agents on human ocular fibroblast. Invest Ophthalmol Vis Sci. 1992 Aug; 33 (9): 2693–701. PMID: 1386351.
54. Breusegem C, Spielberg L, Van Ginderdeuren R, et al. Preoperative nonsteroidal anti-inflammatory drug or steroid and outcomes after trabeculectomy: a randomized controlled trial. Ophthalmology. 2010; 117 (7): 1324–30. doi:10.1016/j.ophtha.2009.11.038
55. Iyer JV, Zhao Y, Lim FPM, Tong L, Wong TTL. Ocular lubricant use in medically and surgically treated glaucoma: a retrospective longitudinal analysis. Clin Ophthalmol. 2017; 11: 1191–6. doi:10.2147/OPTH.S134570
56. Prabhasawat P, Ruangvaravate N, Tesavibul N, Thewthong M. Effect of 0.3% Hydroxypropyl Methylcellulose/Dextran versus 0.18% Sodium Hyaluronate in the treatment of ocular surface disease in glaucoma patients: A randomized, double-blind, and controlled study. J Ocul Pharmacol Ther. 2015; 31 (6): 323–9. doi:10.1089/jop.2014.0115
57. Pauloin T, Dutot M, Warnet JM, Rat P. In vitro modulation of preservative toxicity: high molecular weight hyaluronan decreases apoptosis and oxidative stress induced by benzalkonium chloride. Eur J Pharm Sci. 2008; 34 (4–5): 263–73. doi:10.1016/j.ejps.2008.04.006
58. Alpar JJ. Sodium hyaluronate (Healon) in glaucoma filtering procedures. Ophthalmic Surg. 1986 Nov; 17 (11): 724–30. PMID: 3808582.
59. Sherwin JC, Ratnarajan G, Elahi B, Bilkiewicz-Pawelec A, Salmon JF. Effect of a punctal plug on ocular surface disease in patients using topical prostaglandin analogues: a randomized controlled trial. Clin Exp Ophthalmol. 2018; 46 (8): 888–94. doi:10.1111/ceo.13311
60. Arita R, Morishige N, Shirakawa R, Sato Y, Amano S. Effects of eyelid warming devices on tear film parameters in normal subjects and patients with meibomian gland dysfunction. Ocul Surf. 2015; 13 (4): 321–30. doi:10.1016/j.jtos.2015.04.005
61. Saini M, Dhiman R, Dada T, Tandon R, Vanathi M. Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications. Eye (Lond). 2015; 29 (6): 808–14. doi:10.1038/eye.2015.40
62. Perez VL, Pflugfelder SC, Zhang S, et al. Novel integrin antagonist for treatment of dry eye disease. Ocul Surf. 2016; 14 (2): 207–15. doi:10.1016/j.jtos.2016.01.001
63. Deinema LA, Vingrys AJ, Wong CY, et al. A randomized, double-masked, placebo-controlled clinical trial of two forms of Omega-3 supplements for treating dry eye disease. Ophthalmology. 2017; 124 (1): 43–52. doi:10.1016/j.ophtha.2016.09.023
64. Tellez-Vazquez J. Omega-3 fatty acid supplementation improves dry eye symptoms in patients with glaucoma: results of a prospective multicenter study. Clin Ophthalmol. 2016; 10: 617–26. doi:10.2147/OPTH.S96433
65. Dry Eye A., Management Study Research G, Asbell PA, Maguire MG, Pistilli M, et al. n-3 Fatty acid supplementation for the treatment of dry eye disease. N Engl J Med. 2018; 378 (18): 1681–90. doi:10.1056/NEJMoa1709691
66. Giannaccare G, Pellegrini M, Sebastiani S, et al. Efficacy of Omega-3 fatty acid supplementation for treatment of dry eye disease: A meta-analysis of randomized clinical trials. Cornea. 019; 38 (5): 565–73. doi:10.1097/ICO.0000000000001884
67. Hussain M, Shtein RM, Pistilli M, et al. The Dry Eye Assessment and Management (DREAM) extension study — A randomized clinical trial of withdrawal of supplementation with omega-3 fatty acid in patients with dry eye disease. Ocul Surf. 2020; 18 (1): 47–55. doi:10.1016/j.jtos.2019.08.002
Рецензия
Для цитирования:
Петров С.Ю., Яни Е.В., Филиппова О.М., Епхиева А.Д. Избыточное рубцевание в хирургии глаукомы. Часть 3. Методы предоперационной профилактики. Российский офтальмологический журнал. 2025;18(2):153-159. https://doi.org/10.21516/2072-0076-2025-18-2-153-159
For citation:
Petrov S.Yu., Yani E.V., Filippova O.M., Epkhieva A.D. Wound healing in glaucoma surgery. Part 3. Methods of preoperative prevention. Russian Ophthalmological Journal. 2025;18(2):153-159. (In Russ.) https://doi.org/10.21516/2072-0076-2025-18-2-153-159
Просмотров:
86
Послать статью по эл. почте 